PolarityTE Inc. (PTE)’s Financial Results Comparing With bluebird bio Inc. (NASDAQ:BLUE)

PolarityTE Inc. (NASDAQ:PTE) and bluebird bio Inc. (NASDAQ:BLUE) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PolarityTE Inc. 3 -0.05 13.29M -3.96 0.00
bluebird bio Inc. 81 0.03 55.08M -11.36 0.00

Table 1 highlights PolarityTE Inc. and bluebird bio Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides PolarityTE Inc. and bluebird bio Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
PolarityTE Inc. 448,425,954.04% 0% 0%
bluebird bio Inc. 68,295,102.29% -34% -28.5%

Risk and Volatility

PolarityTE Inc. has a 1.14 beta, while its volatility is 14.00% which is more volatile than Standard and Poor’s 500. In other hand, bluebird bio Inc. has beta of 2.24 which is 124.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of PolarityTE Inc. are 5.6 and 5.6 respectively. Its competitor bluebird bio Inc.’s Current Ratio is 9.3 and its Quick Ratio is 9.3. bluebird bio Inc. can pay off short and long-term obligations better than PolarityTE Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for PolarityTE Inc. and bluebird bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PolarityTE Inc. 0 0 2 3.00
bluebird bio Inc. 0 4 2 2.33

$9.5 is PolarityTE Inc.’s consensus price target while its potential upside is 219.87%. On the other hand, bluebird bio Inc.’s potential upside is 42.14% and its consensus price target is $115.29. The results from earlier shows that analysts opinion suggest that PolarityTE Inc. seems more appealing than bluebird bio Inc.

Institutional & Insider Ownership

The shares of both PolarityTE Inc. and bluebird bio Inc. are owned by institutional investors at 45.6% and 0% respectively. PolarityTE Inc.’s share held by insiders are 33%. Competitively, 0.8% are bluebird bio Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PolarityTE Inc. 8.43% -15% -47.58% -72.95% -77.66% -64.71%
bluebird bio Inc. -8.7% 2.28% -6.01% 0.82% -15.47% 32.29%

For the past year PolarityTE Inc. has -64.71% weaker performance while bluebird bio Inc. has 32.29% stronger performance.

Summary

PolarityTE Inc. beats on 7 of the 12 factors bluebird bio Inc.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.